AngioDynamics Upgraded by Canaccord Genuity to Buy (ANGO)
AngioDynamics (NASDAQ:ANGO) was upgraded by analysts at Canaccord Genuity from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The firm currently has a $20.00 target price on the stock, up from their previous target price of $16.25. Canaccord Genuity’s target price indicates a potential upside of 30.63% from the stock’s previous close.
AngioDynamics (NASDAQ:ANGO) opened at 15.31 on Thursday. AngioDynamics has a 1-year low of $10.53 and a 1-year high of $19.00. The stock has a 50-day moving average of $14.01 and a 200-day moving average of $15.43. The company has a market cap of $540.0 million and a price-to-earnings ratio of 142.08.
AngioDynamics (NASDAQ:ANGO) last released its earnings data on Wednesday, April 9th. The company reported $0.16 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.09 by $0.07. The company had revenue of $88.20 million for the quarter, compared to the consensus estimate of $86.85 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 8.1% on a year-over-year basis. Analysts expect that AngioDynamics will post $0.30 EPS for the current fiscal year.
A number of other firms have also recently commented on ANGO. Analysts at Zacks reiterated a “neutral” rating on shares of AngioDynamics in a research note on Thursday, May 22nd. They now have a $15.00 price target on the stock. Separately, analysts at Raymond James cut their price target on shares of AngioDynamics from $19.00 to $18.00 in a research note on Friday, May 16th. Finally, analysts at TheStreet downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Thursday, April 17th.
AngioDynamics, Inc designs manufacture and sell a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.